Loading stock data…
$2.34-0.10 (-4.10%)
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.34 with a market capitalization of $190M. Wall Street consensus targets $9.00 (5 analysts), implying a +284.6% move over the next 12 months. The stock is currently 49% below its 52-week high of $4.60, remaining 23.5% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$22.87M↓ | -$21.18M↑ | -$21.48M↓ | -$19.07M↑ | -$24.73M |
| Net Income | -$31.63M↑ | -$39.02M↓ | -$10.45M↑ | -$17.46M↓ | -$11.22M |
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amy...